Agreements

* On September 3, 2013, Diaxonhit has entered into a research service agreement with Boehringer Ingelheim for the discovery and characterization of novel splice variants that have the potential to be therapeutic targets for oncology. Through the agreement Boehringer Ingelheim secures an option to acquire the rights to research, develop and commercialize, any targets identified using Diaxonhit’s patented SpliceArray™ discovery platform, with the aim of adding further to its comprehensive research programme to develop innovative new cancer drugs. Diaxonhit will apply its expertise and target discovery platform, built upon its genome wide SpliceArray™ technology, to identify splice variants that are expressed in cancer tissue. These variants will be analyzed using a unique workflow tailored to rapidly identify and characterize novel epitope targets suitable for antibody-based therapeutic development.